bereum co.,ltd, a specialist in postbiotic, led by CEO Hwan Kwon Il, has signed an export and supply contract worth $980,000 for postbiotic pet food with Tecnocalidad of Colombia, under the leadership of CEO Harvey Ibanez Ortiz.Tecnocalidad is a subsidiary responsible for product imports of Agrocamp
Boryung (formerly Boryung Pharmaceutical) announced it will host the “Humans in Space” (HIS) Symposium at the Space Industry Conference in Las Vegas, Nevada from Oct. 23-25.The symposium will be held during the ASCEND conference organized annually by the American Institute of Aeronautics and Astrona
Boryung signed a joint venture agreement with Axiom Space, Inc. in Washington, D.C., on April 25 in the presence of Koo Ja-yeol, chairman of the Korea International Trade Association, who visited the United States as part of an economic mission. The agreement was signed by Kim Jung-kyun, president o
On March 20, Boryung (formerly Boryung Pharmaceutical) and Axiom Space signed an agreement to establish a joint venture (JV) to promote various projects in Low Earth Orbit (LEO). The two parties embarked on detailed discussions to develop the JV in May. Through the JV, Boryung and Axiom Space will j
Boryung Pharmaceutical announced on Feb. 27 that Korean and Mexican cardiovascular internal medicine experts shared the clinical effects and prescription cases of the Kanarb product group at the International Cardiovascular Intervention Conference held in Mexico on Feb. 23 (local time).At this event
Boryung Co. announced on Dec. 21 that it has decided to make a strategic investment of US$50 million in Axiom Space, Inc., a U.S. company promoting the construction of the world’s first commercial space station.In early 2022, Boryung announced the “Care in Space” (CIS) project, with the goal of look
Boryung (formerly Boryung Pharmaceutical) announced on Oct. 25 that it has signed an asset acquisition agreement for ‘Alimta (API: pemetrexed)’, a non-small cell lung cancer (NSCLC) treatment, with Eli Lilly and Co. The completion of this transaction is subject to customary regulatory reviews and cl
Pharmaceutical company Boryung has invested US$10 million (about 12.6 billion won) in Axiom Space, a U.S. space company. The Korean drugmaker is expected to set up a pharmaceutical laboratory in a private space station to be built by Axiom Space in 2027.Axiom Space was established in 2016 by experts
The Hankook Korus Consortium, which is to produce 500 million doses of the Sputnik V vaccine, is showing signs of breaking up after Russia requested a change from the production of those for the first vaccination to the production of those for the second vaccination, which is less profitable.CKD Bio
Korea is positioning itself as a global hub for COVID-19 vaccines. Currently, a total of 14 Korean pharmaceutical companies are involved in producing five kinds of COVID-19 vaccines.The CEOs of Samsung BioLogics and Moderna attended a Korea-U.S. vaccine partnership event held in Washington, D.C. on
Boryung Pharmaceutical has signed a contract with SN BioScience for exclusive sale in Korea of the world's first nano-micelle anticancer drug SN-101 (component name: Nanocomposite SN-38).Through this contract, Boryung Pharmaceutical will hold exclusive sales rights in Korea for 10 years after th
Korus Pharm has formed a consortium to produce Russia's Sputnik V COVID-19 vaccine.Korus Pharm signed a memorandum of understanding with seven Korean companies on Feb. 25 to launch the consortium. The seven included Binex, ISU Abxis, Boryung Biopharma, Chong Kun Dang Bio, Quratis, Humedix and An
ViGenCell, a biotechnology affiliate of Boryung Pharmaceutical that specializes in immune cell therapy technologies, has launched a scientific advisory committee composed of immunological and clinical research experts to accelerate the development of treatments for intractable diseases and strengthe
The author is an analyst of Shinhan Investment Corp. He can be reached at shawn1225@shinhan.com. -- Ed. Strong in ETC market with Korea’s first hypertension drug KanarbBoryung Pharmaceutical stands out vs. other, generic drug-focused mid-tier pharmaceuticals in the domestic market, backed by its com
Boryung Pharmaceutical's new high blood pressure drug Tubero (a composite drug for dyslipidemia), which belongs to the company’s Kanarb family of hypertension drugs, made its debut in the Mexican market on Sept. 11 (Korea time).Tubero is Boryung’s fourth product to be introduced in Mexico, follo
Boryung Pharmaceutical and Vigencell announced on Sept. 8 that they have signed an R&D agreement to develop immunocyte therapy. The agreement will pave the way for the two companies to cooperate in development and commercialization of diverse immune-cell treatments.The agreement will help Vigencell
A group of 10 Korean pharmaceutical and biotech companies have moved into the Cambridge Innovation Center (CIC) in Boston.According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the 10 companies share an office in the CIC in Boston. The 10 companies are Chong Kun Dang, Daewoo
Boryung Holdings announced on Feb. 3 that it established a subsidiary in San Francisco of the United States on Jan. 22 (local time).“We have established the U.S. subsidiary to making efficient investment in the United States by building a network with global pharmaceutical companies, investors and e
Boryung Pharmaceutical Co. announced on Aug. 27 that it has received approval for Phase 1 clinical studies on its anti-cancer therapy “BR2002” from the U.S. Food and Drug Administration (FDA). The Phase 1 clinical trial will be conducted on 90 patients with non-Hodgkin's lymphoma tumors. It is d
Boryung Pharmaceutical Co. announced on Aug. 19 that it has started selling its new antihypertensive combination drug Arahkor Duo, known as Dukarb in South Korea, in Mexico.Arahkor Duo is the third drug that Boryung launches in Mexico after Arahkor, known as Kanarb in South Korea, in 2014 and Diarak